Skip to content
Open access

Association of Life’s Essential 8 and its components with adverse cardiovascular and kidney events in patients with atherosclerotic cardiovascular disease: a prospective cohort study

Oct 2026 · European Heart Journal · 0 citations

TL;DR

Optimal Life’s Essential 8 cardiovascular health is associated with lower risk of MACEs and CKD progression in ASCVD patients, with smoking and glucose as primary modifiable drivers of residual risk for MACEs, and glucose, BMI and smoking for CKD.

Abstract

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of global mortality. Despite advances in primary prevention and acute management, patients with established ASCVD face high residual risks for recurrent major adverse cardiovascular events (MACEs) and chronic kidney disease (CKD) progression. Life’s Essential 8 (LE8) metric has demonstrated inverse associations with cardiovascular outcomes in general populations and high-risk groups like diabetes or CKD patients. However, evidence on LE8 in secondary prevention for patients with ASCVD is limited, with no studies quantifying population attributable fractions (PAFs) for components or residual risks compared to non-ASCVD individuals. Patients with ASCVD have a high residual risk of recurrent MACEs and CKD progression. We evaluated the association of LE8 score and its eight components with MACEs and CKD in ASCVD patients, and determined whether optimal cardiovascular health can mitigate the excess risk compared to non-ASCVD patients. This study included a large prospective cohort with ASCVD (n = 10,635, mean age 61.5 ± 6.2 years, 75.7% male). Participants were categorised into low, medium, and high cardiovascular health groups based on LE8 score categories. Cox proportional hazards models were used to evaluate the associations between these groups and study endpoints. PAFs were calculated to estimate the proportion of adverse events attributable to suboptimal levels of each LE8 component. Additionally, Cox models were applied to assess the effect of LE8 components control after matching participants with ASCVD to those without ASCVD (n = 17,878). Over a median follow-up of 12 years, 2,168 (20.4%) MACEs and 1,350 (12.7%) CKD events occurred. Compared with high cardiovascular health, the low group had about 133% higher risk for MACEs (hazard ratios (HRs) 2.33, 95% confidence interval (CI) 1.83–2.96, P < 0.001) and about 168% higher risk for CKD (HR 2.68, 95% CI 1.95–3.68, P < 0.001), respectively. The overall PAF for MACEs were associated with glucose control (13.7%, 95% CI 10%-17%, P < 0.001) and smoking (12.6%, 95% CI 7%-18%, P = 0.003); and glucose control (19.6%, 95% CI 15%-24%, P = 0.003), BMI (24.4%, 95% CI 11%-35%, P = 0.003) and smoking (13.9%, 95% CI 7%-20%, P = 0.003) for CKD. Compared with non-ASCVD individuals (n = 17,878), ASCVD patients in the highest LE8 score quartile can mitigate the risk of MACEs (HR 1.23, 95% CI 1.00–1.52, P = 0.055) and CKD risk (HR 1.16, 95% CI 0.88–1.53, P = 0.299). Optimal Life’s Essential 8 cardiovascular health is associated with lower risk of MACEs and CKD progression in ASCVD patients, with smoking and glucose as primary modifiable drivers of residual risk for MACEs, and glucose, BMI and smoking for CKD. ASCVD patients who achieve optimal LE8 control may partially mitigate excess MACEs and CKD risk compared with matched non-ASCVD individuals.Cox proportional hazards models results

Read PDF

Similar papers

Open access Oct 2026

Inflammation is associated with high disease burden and adverse outcomes in patients with atherosclerotic cardiovascular disease and chronic kidney disease: a real-world evidence study

Atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD) often coexist, worsening patient prognosis. Inflammation, commonly assessed by C-reactive protein (CRP), is a potential therapeutic target. Trials of inflammation-targeted therapies highlight the need for evidence on the clinical impa...

S. Minha, A. E. Alon Eisen, A. R. Ariel Roguin et al. · 0 citations
Open access Oct 2026

The independent association of mortality with LDL-C management, and number and types of atherosclerotic cardiovascular disease events: a large nationwide real-world cohort study

In a large nationwide cohort, recurrent ASCVD events and multi-bed disease were associated with markedly higher mortality compared to patients experiencing single ASCVD events, highlighting the need for earlier, more intensive, and sustained prevention- particularly aggressive LDL-C lowering and comprehensive risk fact...

M. H. Moshe Hoshen, V. B. Vishal Bali, S. Moser et al. · 0 citations
Open access Sep 2026

The association of cardiovascular disease (CVD) with progression of advanced fibrosis risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

Objective: Advanced fibrosis is the best predictor of future severe liver outcomes in patients with metabolic dysfunction associated steatotic liver disease (MASLD). Our study aims to determine the association between cardiovascular disease (CVD) with time to a high-risk Fibrosis-4 Index (FIB-4) in patients with low-ri...

Myra Quiroga, K. Anderson, Jing-Wen Zhang et al. · 0 citations
Open access Oct 2026

Low-grade inflammation and cardiovascular events among patients with chronic kidney disease.

In CKD patients not yet on kidney replacement therapy, systemic low-grade inflammation, measured through hs-CRP, is associated with occurrence of cardiovascular events independently of traditional risk factors, including a history of ASCVD.

J. Motiejūnaitė, Leila Benamara, Emilie Moutard et al. · 0 citations
Open access Oct 2026

Association between elevated C-reactive protein and mortality, healthcare resource utilization and costs in patients with atherosclerotic cardiovascular disease and/or chronic kidney disease

Atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD) impact health and healthcare systems. Inflammation is a potential modifiable risk factor for both conditions. The case for evaluating the modification of inflammation in these conditions could be strengthened by evidence that systemic...

Kausik K. Ray, Fotis Barkas, E. Huisman et al. · 0 citations
Open access Oct 2026

Comparing the prevalence of cardiovascular inflammation in women and men with atherosclerotic cardiovascular disease with and without chronic kidney disease: a sub-analysis of the POSEIDON study

Cardiovascular (CV) inflammation, defined as high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, is often present in individuals with atherosclerotic cardiovascular disease (ASCVD) with or without chronic kidney disease (CKD). However, there are limited data regarding disparities in the prevalence of CV inflamma...

G. Liuzzo, J. Amerena, S. Genth-Zotz et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.